Biofil Chemicals & Pharmaceuticals share news, announcements and annual reports
NSE: BIOFILCHEMBSE: 524396Pharmaceuticals & BiotechnologySmall Cap
Biofil Chemicals & Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1994 on BSE, Jun 1996 on NSE
Last close ₹28.68down ₹0.73 (2.48%)BSE ₹29.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹29.41.
30 Oct: open ₹29.00, high ₹29.80, low ₹28.26
52-week range of traded prices to 30 Oct 2026
₹25.60Low, 30 Mar 2026₹46.34High, 3 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹47 Cr3,363rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 96.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.16
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 2.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.14
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,71974.4% delivered
Biofil Chemicals & Pharmaceuticals board meetings
116 filed, newest first. Page 3 of 3.
Feb 2011
21 Feb · Board meeting
To consider the matter relating to re-issuance of the forfeited 5712500 equity shares of Rs. 10 each.9 Feb · Board meeting
To take on record the Un-audited Financial Results of the Company for the quarter ended on December 31, 2010.
Nov 2010
12 Nov · Board meeting
To take on record the Un-audited Financial Results of the Company for the quarter ended on September 30, 2010.
Aug 2010
10 Aug · Board meeting
To take on record the Un-audited Financial Results of the Company for the quarter ended on June 30, 2010.
Jan 2010
13 Jan · Board meeting
Meeting on 30 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”
Oct 2009
16 Oct · Board meeting
Meeting on 31 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jun 2009
11 Jun · Board meeting
To consider and approve the Audited Financial Result for Quarter as well as the year ended March 31,2009.
Jan 2009
16 Jan · Board meeting
Meeting on 31 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
14 Oct · Board meeting
Meeting on 31 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”
Jul 2008
14 Jul · Board meeting
Meeting on 31 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Jan 2008
17 Jan · Board meeting
To take on record and aprove the Un-audited Financial Results of the Company for the quarter ended December 31, 2007. Further The results of the postal ballot will be declared by the Chairman and Managing Director of the Company on January 31, 2008.
Dec 2007
6 Dec · Board meeting
Biofil Chemicals & Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company in their meeting held on December 05, 2007 have decided to sell the unit situated at the Sanwer Road, Indore subject to approval of the members by way of postal ballot and for this purpose Mr. L.N. Joshi Company Secretary in practice be and is hereby appointed as scrutinizer.
Nov 2007
29 Nov · Board meeting
To transact the following business: (1) To consider the matter of sale, lease or otherwise dispose of the Manufacturing unit situated at Sanwer Road, Indore, M.P in terms of Section 293 (1) (a) read with 192A of the Companies Act.1956. (2) To appoint scrutinizer to conduct the postal ballot process in fair and transparent manner in terms of section 192A of the Companies Act, 1956.
Oct 2007
19 Oct · Board meeting
Meeting on 31 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Jul 2007
17 Jul · Board meeting
Meeting on 31 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Jan 2007
8 Jan · Board meeting
Meeting on 31 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”